Leverage & Debt Maturities
Clorox’s balance sheet carries a moderate debt load, which is poised to increase with a pending acquisition. As of December 31, 2025, the company had about $2.79 billion in total debt on its books (www.prnewswire.com) (www.prnewswire.com). The vast majority is long-term borrowing (approximately $2.49 billion in long-term notes) with a small portion (<$0.3 billion) in short-term loans and notes payable (www.prnewswire.com) (www.prnewswire.com). Clorox has taken advantage of historically low interest rates in past years to lock in fixed-rate financing. Notably, in May 2022 it issued 4.40% senior notes due 2029 and 4.60% notes due 2032, among other financings (www.sec.gov). These bonds, and similar longer-term notes, mean Clorox faces no imminent large debt maturities in the next couple of years. Its debt maturity schedule is staggered into the late 2020s and early 2030s, reducing short-term refinancing risk. The only major near-term obligation was the Glad® joint venture buyout: Clorox and partner Procter & Gamble agreed to end their Glad bags JV on Jan 31, 2026, with Clorox required to purchase P&G’s 20% stake for cash. The estimated fair value of P&G’s interest was about $476 million, an amount Clorox had already accrued as payable within one year (www.sec.gov). This ~$500 million payout in early 2026 will increase debt or use cash on hand, but it was anticipated and reserved for in Clorox’s liabilities (www.sec.gov). Aside from that JV payment, Clorox’s nearest bond maturities are still several years out, thanks to prior refinancing.
Looking ahead, Clorox’s leverage will rise substantially due to its planned acquisition of GOJO Industries, the maker of Purell® hand sanitizers. In January 2026, Clorox announced an agreement to buy GOJO for $2.25 billion in cash (www.axios.com). This transformative deal expands Clorox’s health & hygiene portfolio (bringing an ~$800 million revenue business into the fold) (www.axios.com), but funding it will likely mean new debt issuance or drawing on credit lines, given Clorox had only ~$227 million in cash on hand at year-end 2025 (www.prnewswire.com). Clorox’s CFO, Luc Bellet, has outlined a prudent financial plan for the post-GOJO era: The acquisition is expected to push debt leverage to around 3.6× EBITDA initially, but management aims to bring leverage back down to ~2.5× by 2027 (www.gurufocus.com). Achieving this will rely on the company’s strong cash flows and anticipated tax benefits from the deal (possibly via goodwill amortization), as well as disciplined capital allocation (www.gurufocus.com). Notably, Clorox plans to prioritize dividend maintenance over share buybacks until it meets the debt-reduction target, effectively pausing any significant repurchases while it pays down debt from the GOJO purchase (www.gurufocus.com). This signals management’s commitment to safeguarding the balance sheet and keeping its investment-grade credit profile intact. Indeed, Clorox has historically operated with moderate leverage for a consumer staples firm – roughly 2× net debt/EBITDA in recent years – and the company appears mindful of not overstretching. Clorox’s existing debt is mostly fixed-rate, insulating it from rising interest rates, and its overall debt-to-capital ratio is manageable. Total debt of ~$2.8 billion against a market capitalization near $15 billion (pre-GOJO) put debt at roughly 15% of enterprise value, though that will increase after the acquisition. The planned deleveraging via cash flow over the next 1–2 years should help return Clorox to a conservative leverage stance by FY2027 (www.gurufocus.com). In summary, Clorox’s debt maturity profile is favorable in the near term, and while leverage will jump with the Purell acquisition, management has a clear strategy (and historically strong free cash generation) to reduce debt over time.
Interest Coverage
Clorox’s ability to service its debt has remained strong, underpinned by healthy earnings relative to interest obligations. The company’s interest expense was about $25 million in the latest quarter (Oct–Dec 2025), up slightly from $22 million in the prior-year period (www.prnewswire.com). On an annualized basis, interest expense is running around ~$100 million or a bit less. By contrast, Clorox’s operating profits far exceed that level. In fiscal Q2 2026, Clorox reported $215 million in earnings before income taxes (EBT) (www.prnewswire.com) – which, after adding back ~$25 million interest, implies roughly $240 million in EBIT for the quarter. This means EBIT covered quarterly interest expense about 9.6×. Even on an EBT basis (post-interest), interest coverage was ~8.6× ($215 M EBT vs $25 M interest) (www.prnewswire.com) (www.prnewswire.com). Such coverage ratios (8–10×) indicate ample cushion: Clorox can comfortably pay its interest costs with earnings, even if profits were to weaken. For the full fiscal year 2025, a similar pattern held – times-interest-earned was in the high single digits. This reflects Clorox’s moderate debt levels and the relatively low coupons on its bonds (mostly in the 3–5% range). It’s worth noting that Clorox’s interest burden did tick up in late 2025 as the company tapped short-term borrowings (notes payable rose to $307 million from virtually nothing) (www.prnewswire.com) (www.prnewswire.com), likely to prefund obligations like the Glad JV payout or other needs. Still, interest expense remains a small fraction of operating income.
Post-GOJO, we can expect interest costs to rise (the ~$2.25 billion financing might carry interest in the mid-single-digit percentages, adding perhaps $120+ million annually in interest). That will naturally compress interest coverage in the near term. For example, if debt doubles and interest expense roughly doubles, Clorox’s EBIT/interest coverage could decrease to the ~4–5× range initially. This is still an adequate cover for an investment-grade company, though notably tighter than before. The CFO’s plan to deleverage (reduce debt/EBITDA from ~3.6× to ~2.5× by 2027) (www.gurufocus.com) will be important to improving those coverage metrics again. Clorox’s strong cash flow generation and stable EBITDA should allow it to bring interest coverage back up over time by paying down debt and growing earnings. Crucially, Clorox has emphasized it will suspend share buybacks until leverage comes down (www.gurufocus.com) – effectively reallocating cash that might have gone to repurchases toward debt reduction, which supports future interest coverage.
At present, Clorox’s interest coverage is robust, and even in stress scenarios the company has managed to meet obligations without issue. For instance, during the FY2024 downturn (when a cyber incident and a weak first half crimped profits), Clorox still maintained its debt service and dividend, drawing on its balance sheet strength. Additionally, the majority of Clorox’s debt is at fixed rates, so rising market interest rates do not immediately impact its existing interest expense. The company also retains access to bank credit facilities for liquidity if needed. Overall, debt serviceability is a bright spot in Clorox’s financial profile – the company’s core operations generate sufficient earnings and cash to comfortably cover interest, and management is proactively managing leverage to keep it that way.
Valuation and Comparables
Clorox’s valuation reflects its defensive nature and recent earnings volatility. At around $125 per share, CLX currently trades near 19–20× trailing 12-month earnings (www.macrotrends.net). For context, as of mid-February 2026, Clorox’s stock price was about $126 and its TTM diluted EPS about $6.37, yielding a P/E ratio just under 20 (www.macrotrends.net). This multiple is in line with, or slightly below, the broader market’s P/E and a bit lower than some larger consumer staples peers. Industry giants like Procter & Gamble or Colgate-Palmolive typically command P/Es in the low-to-mid 20s, albeit with faster organic growth. Clorox’s multiple has normalized after a turbulent period – notably, during FY2024 when one-off losses shrank EPS, Clorox’s P/E temporarily spiked above 50 (as the stock price held up while earnings dropped) (www.macrotrends.net). As earnings recovered in FY2025, the P/E reverted to the high-teens (www.macrotrends.net). The current ~20× earnings valuation suggests the market views Clorox as a stable but low-growth franchise, pricing in expectations of modest EPS growth (or possible near-term stagnation) coupled with the safety of its dividend.
In terms of yield and cash flow metrics, Clorox stands out for its income. The stock’s ~4% dividend yield (www.digrin.com) is well above the S&P 500 average (~1.5%–2%) and higher than most household products peers. Many consumer staples companies yield in the 2–3% range; Clorox’s elevated yield indicates investors demand more income to compensate for slower growth and recent earnings hiccups. The free cash flow yield (FCF/price) roughly mirrors the dividend yield since Clorox pays out a large portion of its FCF as dividends. For example, in FY2025 Clorox generated enough free cash to cover the ~$595 million in dividends, but not a great deal more – implying an FCF yield on the order of 4–5%. This is adequate, though not deeply undervalued. On an EV/EBITDA basis, CLX trades around the low double-digits (estimated ~13× enterprise value to EBITDA using FY2025 figures). That is fairly typical for a mature consumer staples firm; by comparison, faster-growing names might trade at higher EV/EBITDA multiples, whereas companies facing distress or secular decline would trade lower. Clorox’s valuation multiples thus paint a picture of a defensive stock with moderate expectations.
It’s worth noting that Clorox’s share price had swung significantly in recent years – it soared above $200 in 2020 amid pandemic-driven demand for cleaning products, then gradually came down as those trends normalized. Today’s ~$125 stock price is a far cry from that peak, reflecting the comedown in sales and margins since the pandemic highs. The Wells Fargo target of $125 is essentially at the market price, reinforcing that Wall Street sees Clorox as fairly valued at current levels (finviz.com). Other analysts’ targets cluster in the low- to mid-$100s (e.g. BofA at $112, Redburn at $117) (finviz.com), mostly with neutral ratings – indicating consensus that upside may be limited unless Clorox can reignite growth or significantly improve margins. In comparison to peers, Clorox’s 4% yield and ~20 P/E suggest a somewhat value-oriented profile within the sector: for instance, a peer like Church & Dwight (with higher growth) trades at a richer multiple but a lower yield, whereas Kimberly-Clark (another staples firm with 3–4% yield) trades around a similar earnings multiple.
From a valuation risk standpoint, Clorox doesn’t appear grossly overextended in price – if anything, the market is taking a cautious stance. The stock’s defensive characteristics (strong brand portfolio, steady dividend) support a premium to the market in downturns, but its recent operational setbacks have likely capped the multiple for now. Any significant recovery in earnings (through cost improvements or synergies from acquisitions) could allow some multiple expansion, while any further earnings disappointments could pressure the stock lower. In sum, Clorox is valued as a stable cash-generative business with limited growth, and the current price/target reflects that balance of reliable dividends against uncertain near-term growth prospects.
Risks and Red Flags
Despite its defensive reputation, Clorox faces several risks and red flags that investors should monitor. Profitability pressures are a central concern. The company’s gross margins have been under strain due to high input costs (commodities, manufacturing and logistics expenses) and other headwinds. In the most recent quarter, gross margin fell to 43.2%, down 60 basis points year-on-year despite price increases, primarily because manufacturing and freight costs climbed faster than cost savings could offset (www.prnewswire.com). Over the past couple of years, Clorox has seen its margins seesaw with inflation: resin for trash bags, chemicals for cleaning products, and transportation costs all spiked, squeezing profits. While some of these costs have moderated, Clorox is still working to rebuild margins to pre-inflation levels. Bank of America’s analysts noted that Clorox’s fiscal Q2 earnings came in below expectations specifically due to “gross margin pressure from higher costs,” and they remain cautious with “tepid forecasts” given uncertainty around improvements in consumption and margins ahead (www.insidermonkey.com). This highlights the risk that cost inflation or an inability to raise prices further could keep margins subdued. Any stagnation in margin recovery would directly hinder earnings growth and cash flow, pressuring the payout ratios and valuation.
On the demand side, Clorox is experiencing soft consumption trends in certain categories. In the latest quarter, net sales were actually down 1% year-over-year on an organic basis, and Clorox attributed the decline “primarily [to] lower consumption” by consumers (www.prnewswire.com). Some of this is normalization – during the pandemic, households stocked up on cleaning and disinfecting products, and those tailwinds have faded. But it also suggests Clorox isn’t getting volume growth, and in some cases volume is declining as consumers shift to larger pack sizes or perhaps to competitors/store brands (www.prnewswire.com). The company has leaned on price increases in the past two years to drive revenue, but there is a risk of price elasticity: further hikes might dampen demand or push customers to cheaper alternatives. Clorox must rely on product innovation and marketing to spur demand in a challenging environment where category growth is only stabilizing at low levels (www.insidermonkey.com). If overall consumption of its products continues to tick down (e.g. consumers use less bleach as COVID memories fade, or switch disinfectant brands), Clorox could face stagnant or declining organic sales.
Clorox’s recent operational hiccups also raise red flags in execution. In August 2023, Clorox suffered a major cyberattack that disrupted its manufacturing and distribution operations for weeks. The incident forced the company to manually process orders and resulted in product shortages on shelves. Clorox incurred significant costs related to this attack, though insurance covered part of the losses (www.prnewswire.com). The company disclosed a $25 million one-time benefit in late 2024 from insurance recovery, implying the gross impact of the cyber event was even larger (www.prnewswire.com). This underscores a risk of cybersecurity and IT system vulnerability – a non-traditional risk for a bleach and chemicals company, but very real as Clorox modernizes its systems. In fact, Clorox has been undergoing a major ERP (enterprise resource planning) system upgrade, which itself poses execution risk. During the ERP transition in mid-2025, Clorox had to ship about two extra weeks of inventory to retailers in advance, to avoid disruptions (www.prnewswire.com). This smoothed the rollout, but now retailers are drawing down those inventory buffers, contributing to weaker shipments in FY2026 (www.prnewswire.com). Any glitches in the new ERP system or further cyber incidents could hurt Clorox’s ability to fulfill orders and manage its supply chain. The company acknowledges that as these systems go live, it may face “integration challenges [and] system inefficiencies” that could impact operations in the short term (www.sec.gov). Investors should be alert to any commentary on supply chain or IT disruptions, as these can have outsized effects (the 2023 attack caused an estimated tens of millions in lost sales and extra costs).
Another risk flagged by recent events is M&A execution and capital allocation. Clorox’s foray into the health supplements business – the 2018 acquisition of brands like RenewLife and Natural Vitality (the VMS – Vitamins, Minerals, Supplements – segment) – turned out poorly. The company divested its VMS business in late 2024 at a loss, taking a $118 million after-tax charge to write down that venture (www.prnewswire.com). The sale of the Better Health VMS unit (along with an Argentina business) was meant to refocus Clorox on core areas, but the episode reveals a misstep: management invested in a non-core category and had to reverse course at a significant cost (www.prnewswire.com). This raises questions about Clorox’s acquisition strategy and integration capability, which is very pertinent now as it pursues the much larger GOJO deal. The GOJO acquisition will be Clorox’s biggest in years – and while hand hygiene fits more naturally with Clorox’s core (cleaning, disinfecting) than vitamins did, integration risks are still present. Clorox will need to smoothly combine GOJO’s operations, retain its institutional customers, and achieve promised synergies to make the $2.25 billion price tag pay off. If Clorox stumbles in integrating GOJO or if Purell sales don’t grow as expected, the company could find itself with a heavy debt load and underperforming asset on its hands. Additionally, any delay in the deal’s accretion timeline (management expects the deal to be roughly EPS-neutral in year one and accretive by FY2027) could disappoint investors. There are also regulatory and legal compliance risks whenever bringing a new product line – the AInvest analysis of the GOJO deal highlighted that Clorox will need to be diligent about product safety and oversight, given past issues in quality control industry-wide (www.ainvest.com).
Financially, higher leverage itself is a risk. As discussed, Clorox’s debt will jump and interest costs will rise after the GOJO acquisition. That means less financial flexibility in the short term – the company will have to dedicate more cash to interest and debt repayment. If another unforeseen downturn hits earnings (for example, a recession causing consumers to trade down, or an unexpected liability), Clorox would have less of a buffer than it did with a leaner balance sheet. The company’s credit rating could come under pressure if leverage stays elevated longer than expected. That said, Clorox appears conscious of this risk and has laid out a plan to reduce debt (and crucially, has halted share buybacks to conserve cash (www.gurufocus.com)). The dividend has been maintained through rough patches, but investors should watch Clorox’s payout ratio going forward – in a severe earnings decline, the current payout (nearly $5/share annually) could become challenging to sustain alongside high debt servicing needs.
Finally, competitive and market risks persist. Clorox competes with giant multinationals and private-label store brands in many of its categories (e.g. Lysol from Reckitt, store-brand bleach and bags, etc.). Market share losses or aggressive promotion by rivals could hurt Clorox’s volumes. The company’s international segment and professional products unit introduce some exposure to economic cycles and geopolitical factors (though they are a smaller portion of sales). Regulatory and ESG risks shouldn’t be ignored either: Clorox’s products involve chemicals (bleach, pesticides in disinfecting wipes, etc.) that are subject to environmental and safety regulations. Any tightening of rules (for example, restrictions on certain cleaning agents or single-use plastic trash bags) could force product reformulations or impact demand. Clorox also promotes its sustainability leadership (being ranked highly on Barron’s sustainability list) (www.prnewswire.com), so a failure to meet those standards or a reputational issue (e.g. a product recall or safety issue) would be a risk to its brand image.
In summary, Clorox’s key risks include margin pressures from high costs, soft consumer demand in a post-COVID environment, operational disruptions (IT systems, cyber threats), and integration/leveraging risks tied to its acquisition strategy. The company’s recent history – a big earnings dip in 2024, a costly divestiture, and a cyber-induced supply shock – underlines that even a stable staples business can hit potholes. Investors should keep an eye on Clorox’s execution in improving margins and delivering on its new acquisition, as well as its ability to navigate any further external shocks. The high dividend yield is a double-edged sword: it provides cushion via income, but also signals that the market is a bit wary about Clorox’s near-term growth trajectory (a red flag in itself). If Clorox fails to address these challenges, the stock could languish or fall further; however, effective execution could restore confidence and upside.
Outlook and Open Questions
Looking ahead, Clorox’s outlook hinges on a few critical questions. First, can the company restore growth in its core businesses? Management has reaffirmed its full-year fiscal 2026 guidance but expects net sales to decline 6%–10% (including a ~1 point drag from a divested business) (www.prnewswire.com). Even adjusting for the one-time ERP inventory timing, this points to flat-to-slightly positive organic sales at best. Volume recovery is an open question – with consumption having trended lower, investors are watching whether Clorox’s back-half plans (new products and marketing investments) will drive a pickup in demand. CEO Linda Rendle has expressed confidence in a “strong slate of innovation” for H2 2026 and beyond (www.prnewswire.com). New products (e.g. in cleaning wipes, litter, Brita filters, etc.) and increased advertising could help stabilize volumes. But it remains to be seen if end-market demand for categories like household cleaners will grow meaningfully, or if they have reached a new post-pandemic baseline. A related question is whether retail inventory levels will normalize – Clorox’s recent sales were buffeted by inventory buildup and drawdown around its ERP change, so underlying run-rate demand is a bit murky. Investors will want to see a return to consistent organic sales growth (mid-single-digits) longer term, something that has proved elusive recently.
Secondly, how quickly and effectively will Clorox integrate GOJO Industries, and what does that mean for earnings? The Purell acquisition provides opportunities (cross-selling, expanding in health-care disinfectants, etc.), but also raises execution questions. Clorox forecasts the deal to be EPS-neutral in year one and accretive thereafter, with accretion by fiscal 2027 (www.ainvest.com). Achieving this will require hitting synergy targets and possibly some growth acceleration in GOJO’s sales. Open questions include: will Clorox be able to retain GOJO’s large institutional customers (businesses, hospitals) and leverage its distribution network to grow that business? Will there be any cultural or operational integration hiccups blending the two companies? Moreover, with the high leverage (3.5×+ debt/EBITDA initially) that comes with the deal (www.gurufocus.com), how much flexibility will Clorox have if the integration takes longer or costs more than expected? The company says it will focus on debt reduction and refrain from stock buybacks until leverage is down to target (www.gurufocus.com). An open question is whether Clorox can simultaneously invest in growth initiatives (innovation, marketing) and meet its debt paydown goals – essentially balancing growth and deleveraging. The outcome of that balancing act will shape Clorox’s earnings trajectory and shareholder returns over the next few years.
Another area of uncertainty is margin improvement. Clorox’s outlook assumes some gross margin uplift (management has been pursuing cost savings programs and pricing actions). However, will input cost relief and cost-saving projects be enough to significantly lift margins? BofA analysts remain cautious, citing uncertainty around margin improvement in their forecasts (www.insidermonkey.com). If commodities like resin or pulp rise again, or if Clorox faces higher costs from labor or distribution, it could blunt margin recovery. Conversely, any unexpected cost tailwinds (e.g. a drop in oil prices reducing plastic and transport costs) could boost margins faster. Product mix is another factor – Clorox’s portfolio spans higher-margin items (like wipes or cleaning chemicals) and lower-margin ones (like trash bags). Growth in the latter (or declines in the former) can mix down profitability. Management’s ability to execute on their IGNITE strategy (Clorox’s strategic plan focusing on innovation, digital, and cost efficiency) will be tested in this environment. An open question is how much operating leverage Clorox can achieve if and when sales turn upward – will a return to modest sales growth translate to outsized earnings growth via margin expansion, or will gains be incremental?
Additionally, the market dynamic for consumer staples stocks presents a question mark. Staples had a strong start in early 2026 as investors rotated into defensive sectors (finviz.com). Wells Fargo highlighted that this is the best start for Staples vs the S&P on record (finviz.com). One open question is whether this rotation has staying power. If economic sentiment shifts and risk appetite increases (for example, if interest rates fall or growth stocks come back in favor), staples like Clorox could see their relative performance wane. Clorox, being a higher-yielding staples stock, might especially lag in a rising market scenario. Thus, a question for investors is to what extent Clorox’s near-term stock performance will be driven by company-specific improvements versus sector-wide investor flows. So far, analysts’ neutral ratings suggest they see Clorox more as a “hold” in a staples rotation rather than a clear outperformer on fundamentals (www.ainvest.com). If Clorox surprises with better results (or conversely, if it hits another bump), that could change the narrative.
In terms of shareholder returns and capital allocation, open questions include Clorox’s commitment to the dividend growth streak in the face of higher debt. The company has indicated dividends remain a priority and that it will sacrifice buybacks first if needed (www.gurufocus.com). Given the nearly 50-year streak of hikes, it’s very likely Clorox will still announce a token increase in 2026 (to keep the streak alive) (www.kiplinger.com). The question is more how large future increases can be – if earnings per share are flat or only slightly up in the next couple years, dividend hikes may remain in the 1–3% range annually. Some investors might question if those minimal raises are worth it, or if resources should be conserved for debt reduction. However, given Clorox’s culture and investor base, a cut or pause in dividend growth would be a last resort. Another question is whether Clorox will revisit share repurchases after reaching its leverage goal. The company has a history of buybacks (treasury stock on the balance sheet has grown, indicating past repurchases) (www.prnewswire.com) – resuming them could provide some support to EPS growth once debt is under control.
Finally, strategic questions remain about Clorox’s long-term positioning. The sale of the VMS business and acquisition of GOJO raise the question of portfolio focus: Will Clorox stick to its knitting in household/health products, or could it consider further divestitures (or acquisitions) to streamline or boost growth? For instance, Glad (trash bags) is now fully owned – will Clorox double down on that space, or might it consider spinning off some non-core categories to focus on higher-margin segments? With the Glad JV resolved and vitamins business gone, Clorox is more concentrated on cleaning, home care, and lifestyle products. How well it capitalizes on consumer trends (e.g. green cleaning products, natural formulations, etc.) is another open question for staying relevant against niche upstarts. The competitive landscape is dynamic: there’s always a risk of innovation by a competitor that could disrupt a category (for example, a new technology in cat litter or a new surface cleaning method). Clorox’s answer is continuous innovation of its own – but the success of those R&D efforts is something to watch.
In conclusion, Clorox finds itself at an inflection point with several open questions. The company’s defensive strengths – strong brands, a reliable dividend, and historical resilience – are weighed against recent challenges and a need to adapt. Can Clorox reaccelerate growth and improve margins in a post-pandemic world? Will the Purell deal be a catalyst for renewed momentum or simply a leveraging event to absorb? These questions will likely determine whether Wells Fargo’s $125 price target proves conservative or optimistic. For now, the stock is priced for caution, and Clorox will have to execute well in the coming quarters to justify any significant re-rating. Investors, in turn, should keep a close eye on the signposts: margin trends, debt paydown progress, dividend coverage, and the integration of GOJO – as the answers to these will shape Clorox’s financial health and shareholder value in the years ahead.
(finviz.com) (www.kiplinger.com) (www.kiplinger.com) (www.digrin.com) (mlq.ai) (www.prnewswire.com) (www.kiplinger.com) (www.prnewswire.com) (www.sec.gov) (www.sec.gov) (www.gurufocus.com) (www.gurufocus.com) (www.prnewswire.com) (www.prnewswire.com) (www.prnewswire.com) (www.insidermonkey.com) (www.prnewswire.com) (www.prnewswire.com) (www.prnewswire.com)
